Halofuginone: A potent inhibitor of critical steps in angiogenesis progression

FASEB Journal

Volumn 14, Issue 15, 2000, Pages 2477-2485

  Elkin, M ^a   Miao, H Q ^a   Nagler, A ^a   Aingorn, E ^a   Reich, R ^a   Hemo, I ^a   Dou, H L ^a   Pines, M ^a   Vlodavsky, I ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Extracellular matrix; Halofuginone; Matrix metalloproteinase 2; Neovascularization; Type I collagen

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIPARASITIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; COLLAGEN TYPE 1; GELATINASE A; HALOFUGINONE;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALIA;

EID: 0033664318     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0292com     Document Type: Article

References (44)

1. Mechanisms of angiogenesis
2. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
3. Anticancer drug targets: Approaching angiogenesis
4. What is the evidence that tumors are angiogenesis dependent?
5. The implications of angiogenesis for the biology and therapy of cancer metastasis
6. Tumor angiogenesis: Therapeutic implications
7. Anti-angiogenesis: New concept for therapy of solid tumors
8. Tumor angiogenesis - New drugs on the block
9. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors
10. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro
11. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
12. Partial purification and characterization of a neutral protease which cleaves type IV collagen
13. Molecular architecture of basement membranes
14. Differential expression of extracellular proteins is correlated with angiogenesis in vitro
15. Transcriptional activity of the alpha 1 (I)-collagen promoter is correlated with the formation of capillary-like structures by endothelial cells in vitro
16. Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium
17. Differentiation of endothelium
18. Extracellular matrix and cell shape: Potential control points for inhibition of angiogenesis
19. Geometric control of cell life and death
20. Regulation of capillary formation by laminin and other components of the extracellular matrix
21. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone
22. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone
23. Halofuginone: An inhibitor of collagen type I synthesis
24. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: Effect of halofuginone
25. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone
26. Halofuginone: A novel antifibrotic therapy
27. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone
28. Clonal growth of bovine vascular endothelial cells: Fibroblast growth factor as a survival agent
29. Antiproliferative activity to vascular smooth muscle cells and receptor binding of heparin-mimicking polyaromatic anionic compounds
30. A rapid in vitro assay for quantitating the invasive potential of tumor cells
31. Small intestinal submucosa: A tissue-derived extracellular matrix that promotes tissue-specific growth and differentiation of cells in vitro
32. Small intestinal submucosa: A substrate for in vitro cell growth
33. Endothelial cell adherence to small intestinal submucosa: An acellular bioscaffold
34. A model of angiogenesis in the mouse cornea
35. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro
36. The extracellular matrix and the control of proliferation of vascular endothelial and vascular smooth muscle cells
37. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone
38. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis
39. Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: Implications for an anti-angiogenic therapy
40. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
41. Angiogenic oligosaccharides of hyaluronan enhance the production of collagens by endothelial cells
42. The role of collagens and proteoglycans in tumor angiogenesis
43. Inhibition of angiogenesis through modulation of collagen metabolism
44. Regulation of angiogenesis in vitro by collagen metabolism